1617529-35-7

Basic information

• Product Name: benzyl-[3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-isoquinolin-1-yl]-amine
• Synonyms: benzyl-[3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-isoquinolin-1-yl]-amine
• CAS NO: 1617529-35-7
• Molecular Weight: 341.456
• Mol File: 1617529-35-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: benzyl-[3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-isoquinolin-1-yl]-amine(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl-[3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-isoquinolin-1-yl]-amine(1617529-35-7)
• EPA Substance Registry System: benzyl-[3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-isoquinolin-1-yl]-amine(1617529-35-7)

Safety Data

• Hazardous Substances Data: 1617529-35-7(Hazardous Substances Data)

Upstream product

• 56341-36-7 1,5-dimethyl-1H-pyrrole-2-carbonitrile 
• 57806-76-5 N,N-diethyl-2,3-dimethyl benzamide 
• 1617529-33-5 3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-2H-isoquinolin-1-one 
• 1617529-29-9 1-chloro-3-(1,5-dimethyl-1H-pyrrol-2-yl)-5-methyl-isoquinoline 
• 100-46-9 benzylamine 

Relevant articles and documents

Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors

A series of 3-heteroarylisoquinolinamines were designed, synthesized and evaluated for cytotoxicity, topoisomerases (topos) inhibitory activities and cell cycle inhibition. Several of the 3-heteroarylisoquinolines exhibited selective cytotoxicity against human ductal breast epithelial tumor (T47D) cells over non-cancerous human breast epithelial (MCF-10A) and human prostate cancer (DU145) cells. Most of the derivatives showed greater cytotoxicity in human colorectal adenocarcinoma (HCT-15) cells than camptothecin (CPT), etoposide and doxorubicin (DOX). Generally, 3-heteroarylisoquinolinamines displayed greater affinity for topo I than topo II. 3-Heteroarylisoquinolinamines with greater topo I inhibitory effect exhibited potent cytotoxicity. Piperazine-substituted derivative, 5b, with potent topo I and moderate topo II activities intercalated between DNA bases and interacted with topos through H-bonds at the DNA cleavage site of a docking model. Moreover, flow cytometry indicated that cytotoxic 3-heteroarylisoquinolinamines led to accumulation of human cervical (HeLa) cancer cells in the different phases of the cell cycle before apoptosis. Taken together, 3-heteroarylisoquinolinamines possessed potent cytotoxicity with topos and cell cycle inhibitory activities.